GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Skye Bioscience Inc (NAS:SKYE) » Definitions » EV-to-EBITDA

Skye Bioscience (Skye Bioscience) EV-to-EBITDA : -7.21 (As of May. 18, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Skye Bioscience EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Skye Bioscience's enterprise value is $259.71 Mil. Skye Bioscience's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-36.02 Mil. Therefore, Skye Bioscience's EV-to-EBITDA for today is -7.21.

The historical rank and industry rank for Skye Bioscience's EV-to-EBITDA or its related term are showing as below:

SKYE' s EV-to-EBITDA Range Over the Past 10 Years
Min: -67.44   Med: -0.75   Max: 22322.75
Current: -7.21

During the past 12 years, the highest EV-to-EBITDA of Skye Bioscience was 22322.75. The lowest was -67.44. And the median was -0.75.

SKYE's EV-to-EBITDA is ranked worse than
100% of 455 companies
in the Biotechnology industry
Industry Median: 10.35 vs SKYE: -7.21

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-18), Skye Bioscience's stock price is $12.05. Skye Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-4.509. Therefore, Skye Bioscience's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Skye Bioscience EV-to-EBITDA Historical Data

The historical data trend for Skye Bioscience's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Skye Bioscience EV-to-EBITDA Chart

Skye Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.91 -1.80 -2.32 -0.83 -1.01

Skye Bioscience Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.69 -0.99 -1.17 -1.01 -10.00

Competitive Comparison of Skye Bioscience's EV-to-EBITDA

For the Biotechnology subindustry, Skye Bioscience's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Skye Bioscience's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Skye Bioscience's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Skye Bioscience's EV-to-EBITDA falls into.



Skye Bioscience EV-to-EBITDA Calculation

Skye Bioscience's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=259.711/-36.024
=-7.21

Skye Bioscience's current Enterprise Value is $259.71 Mil.
Skye Bioscience's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-36.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Skye Bioscience  (NAS:SKYE) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Skye Bioscience's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=12.05/-4.509
=At Loss

Skye Bioscience's share price for today is $12.05.
Skye Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.509.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Skye Bioscience EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Skye Bioscience's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Skye Bioscience (Skye Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
11250 El Camino Real, Suite 100, San Diego, CA, USA, 92130
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. It researches and develops and plans to commercialize cannabinoid derivatives through its own directed research efforts and through several license agreements with the University of Mississippi. The company's lead compound, SBI-100, is initially being developed to treat ocular disease.
Executives
Punit Dhillon director 5820 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
John D Diekman 10 percent owner C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Partners Vii, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Paul A. Grayson director 10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
5am Ventures Vii, L.p. 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kush Parmar 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Partners Ii, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Co-investors Ii Lp 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Versant Ventures Iii, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Scott M Rocklage 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Andrew J. Schwab director, 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Versant Side Fund Iii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
5am Ventures Ii Lp 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Versant Venture Capital Iii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Deborah H. Charych director 1001 17TH ST, SAN FRANCISCO CA 94107